Coherus Oncology (CHRS) Stock: Why It's Down Today
Updated Oct 19, 2026, 12:05 PM ET · intraday price
- Trading at $0.98 as of 12:05 PM ET, -0.52% vs the prior close of $0.99.
- Volume 603.03K shares, 0.4x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CHRS dips 0.5% to $0.98, a 52-week low. Trading at $0.98 (intraday, 12:05 PM ET), -0.52% vs the prior close of $0.99. Day range $0.97–$1.01, opened at $1.00.
CHRS daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 19, 2026 — CHRS dips 0.5% to $0.98, a 52-week low
- Trading at $0.98 (intraday, 12:05 PM ET), -0.52% vs the prior close of $0.99. Day range $0.97–$1.01, opened at $1.00.
- Volume was 603.03K shares, 0.4x its 50-day average of 1.37M — lighter than usual.
- Price is -20.6% vs its 50-day average ($1.24) and -36.6% vs its 200-day average ($1.55).
- 52-week range $0.97–$2.62; the current price sits at 1% of that range, 62.4% below the 52-week high.
Oct 16, 2026 — CHRS slides 7.5% to $0.99, a 52-week low
- Closed at $0.99, -7.48% vs the prior close of $1.07. Day range $0.99–$1.07, opened at $1.07.
- Volume was 938.50K shares, 0.7x its 50-day average of 1.43M.
- Price is -20.5% vs its 50-day average ($1.25) and -36.4% vs its 200-day average ($1.56).
- 52-week range $0.97–$2.62; today's close sits at 1% of that range, 62.2% below the 52-week high.
Oct 15, 2026 — CHRS rises 1.9% to $1.07
- Closed at $1.07, +1.90% vs the prior close of $1.05. Day range $1.03–$1.09, opened at $1.07.
- Volume was 1.54M shares, 1.1x its 50-day average of 1.42M.
- Price is -14.5% vs its 50-day average ($1.25) and -31.3% vs its 200-day average ($1.56).
- 52-week range $0.97–$2.62; today's close sits at 6% of that range, 59.1% below the 52-week high.
Oct 14, 2026 — CHRS dips 1.9% to $1.05
- Closed at $1.05, -1.87% vs the prior close of $1.07. Day range $1.01–$1.09, opened at $1.05.
- Volume was 1.72M shares, 1.2x its 50-day average of 1.39M.
- Price is -16.6% vs its 50-day average ($1.26) and -32.7% vs its 200-day average ($1.56).
- 52-week range $0.97–$2.62; today's close sits at 5% of that range, 59.9% below the 52-week high.
Oct 13, 2026 — CHRS jumps 3.9% to $1.07
- Closed at $1.07, +3.88% vs the prior close of $1.03. Day range $1.00–$1.08, opened at $1.06.
- Volume was 1.34M shares, 1.0x its 50-day average of 1.38M.
- Price is -15.6% vs its 50-day average ($1.27) and -31.5% vs its 200-day average ($1.56).
- 52-week range $0.97–$2.62; today's close sits at 6% of that range, 59.1% below the 52-week high.
Oct 12, 2026 — CHRS slides 3.7% to $1.03
- Closed at $1.03, -3.74% vs the prior close of $1.07. Day range $1.03–$1.07, opened at $1.06.
- Volume was 1.04M shares, 0.8x its 50-day average of 1.37M.
- Price is -19.2% vs its 50-day average ($1.27) and -34.1% vs its 200-day average ($1.56).
- 52-week range $0.97–$2.62; today's close sits at 3% of that range, 60.6% below the 52-week high.
Oct 9, 2026 — CHRS ends flat (+0.0%) to $1.07
- Closed at $1.07, +0.00% vs the prior close of $1.07. Day range $1.05–$1.12, opened at $1.06.
- Volume was 1.70M shares, 1.3x its 50-day average of 1.34M.
- Price is -16.6% vs its 50-day average ($1.28) and -31.6% vs its 200-day average ($1.56).
- 52-week range $0.97–$2.62; today's close sits at 6% of that range, 59.1% below the 52-week high.
Oct 8, 2026 — CHRS jumps 5.9% to $1.07
- Closed at $1.07, +5.94% vs the prior close of $1.01. Day range $0.97–$1.07, opened at $1.01.
- Volume was 2.14M shares, 1.6x its 50-day average of 1.31M.
- Price is -17.1% vs its 50-day average ($1.29) and -31.7% vs its 200-day average ($1.57).
- 52-week range $0.97–$2.62; today's close sits at 6% of that range, 59.1% below the 52-week high.
Oct 7, 2026 — CHRS dips 1.9% to $1.01, a 52-week low, 5 down days in a row
- Closed at $1.01, -1.94% vs the prior close of $1.03. Day range $1.01–$1.08, opened at $1.02.
- Volume was 1.23M shares, 1.0x its 50-day average of 1.29M.
- Price is -22.1% vs its 50-day average ($1.30) and -35.6% vs its 200-day average ($1.57).
- 52-week range $1.01–$2.62; today's close sits at 0% of that range, 61.4% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — CHRS slides 8.0% to $1.03, a 52-week low on 2.4x normal volume
- Closed at $1.03, -8.04% vs the prior close of $1.12. Day range $1.01–$1.13, opened at $1.13.
- Volume was 2.97M shares, 2.4x its 50-day average of 1.24M — unusually heavy trading.
- Price is -21.1% vs its 50-day average ($1.31) and -34.4% vs its 200-day average ($1.57).
- 52-week range $1.01–$2.62; today's close sits at 1% of that range, 60.6% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — CHRS slides 3.4% to $1.12, a 6-month low, 3 down days in a row
- Closed at $1.12, -3.45% vs the prior close of $1.16. Day range $1.08–$1.16, opened at $1.16.
- Volume was 2.01M shares, 1.7x its 50-day average of 1.21M.
- Price is -14.8% vs its 50-day average ($1.31) and -28.7% vs its 200-day average ($1.57).
- 52-week range $1.08–$2.62; today's close sits at 3% of that range, 57.2% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — CHRS ends flat (+0.0%) to $1.16
- Closed at $1.16, +0.00% vs the prior close of $1.16. Day range $1.14–$1.19, opened at $1.19.
- Volume was 1.18M shares, 1.0x its 50-day average of 1.20M.
- Price is -12.1% vs its 50-day average ($1.32) and -26.2% vs its 200-day average ($1.57).
- 52-week range $1.09–$2.62; today's close sits at 5% of that range, 55.7% below the 52-week high.
CHRS bull case vs bear case (from the data)
- Latest fiscal-year net income: profit of $168.02M.
- Price is -20.6% vs its 50-day average — short-term trend is down.
- Price is -36.6% vs its 200-day average — below the long-term trend line.
- Annual revenue fell 100.0% in the latest fiscal year (SEC XBRL).
- Share count up 32.9% in a year (dilution).
- High volatility: average daily move of 3.4% over 20 sessions.
- Thin trading (under $2M a day on average) can mean wide bid/ask spreads.
CHRS latest news & SEC filings
Every SEC filing by or about CHRS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 28, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 28, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 17, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 17, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 1.02 — Ended a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
Aug 5, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$20.63M (prior year $297.77M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.13 (prior year $2.57) (loss widened vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 27, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade CHRS
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 11, 2026, Mar 9, 2026, Jan 13, 2026. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.43% (largest 8.0%). That is a volatile stock.
- Liquidity: about 1.61M shares (≈$1.58M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.98 vs a range of $0.97–$2.62 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Aug 28, 2026; 8-K Aug 17, 2026; 8-K Aug 17, 2026.
- Share count: 154.50M shares outstanding (Jul 31, 2026), +32.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
CHRS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | 1.00 | 1.01 | 0.97 | 0.98 | 603.03K |
| Oct 16, 2026 | 1.07 | 1.07 | 0.99 | 0.99 | 938.50K |
| Oct 15, 2026 | 1.07 | 1.09 | 1.03 | 1.07 | 1.54M |
| Oct 14, 2026 | 1.05 | 1.09 | 1.01 | 1.05 | 1.72M |
| Oct 13, 2026 | 1.06 | 1.08 | 1.00 | 1.07 | 1.34M |
| Oct 12, 2026 | 1.06 | 1.07 | 1.03 | 1.03 | 1.04M |
| Oct 9, 2026 | 1.06 | 1.12 | 1.05 | 1.07 | 1.70M |
| Oct 8, 2026 | 1.01 | 1.07 | 0.97 | 1.07 | 2.14M |
| Oct 7, 2026 | 1.02 | 1.08 | 1.01 | 1.01 | 1.23M |
| Oct 6, 2026 | 1.13 | 1.13 | 1.01 | 1.03 | 2.97M |
| Oct 5, 2026 | 1.16 | 1.16 | 1.08 | 1.12 | 2.01M |
| Oct 2, 2026 | 1.19 | 1.19 | 1.14 | 1.16 | 1.18M |
| Oct 1, 2026 | 1.20 | 1.21 | 1.14 | 1.16 | 709.20K |
| Sep 30, 2026 | 1.18 | 1.23 | 1.15 | 1.21 | 1.58M |
| Sep 29, 2026 | 1.15 | 1.20 | 1.12 | 1.18 | 1.35M |
| Sep 28, 2026 | 1.13 | 1.15 | 1.10 | 1.14 | 1.14M |
| Sep 25, 2026 | 1.17 | 1.18 | 1.13 | 1.13 | 1.22M |
| Sep 24, 2026 | 1.25 | 1.26 | 1.17 | 1.17 | 1.56M |
| Sep 23, 2026 | 1.30 | 1.31 | 1.21 | 1.26 | 1.62M |
| Sep 22, 2026 | 1.39 | 1.39 | 1.22 | 1.30 | 4.54M |
About Coherus Oncology
Coherus Oncology (CHRS) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in REDWOOD CITY, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1512762.
CHRS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Rita A Karachun | Director | Jun 9, 2026 |
| Dennis M Lanfear | President & CEO | Jun 2, 2026 |
| Lee Nisley Newcomer | Director | Jun 9, 2026 |
| Charles W. Newton | Director | Jun 9, 2026 |
| Jill O'Donnell-Tormey | Director | Jun 9, 2026 |
| Michael Lee Ryan | Director | Jun 9, 2026 |
| Ali J. Satvat | Director | Jun 9, 2026 |
| Mats Wahlstrom | Director | Jun 9, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Dennis M Lanfear | President & CEO | Jun 2, 2026 |
| Bryan J Mcmichael | Chief Financial Officer | Jun 2, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
CHRS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $168.02M | 1.43 | $-138.51M |
| Dec 31, 2024 | — | $28.51M | 0.25 | $-20.44M |
| Dec 31, 2023 | — | $-237.89M | -2.53 | $-174.88M |
| Dec 31, 2022 | — | $-291.75M | -3.76 | $-241.12M |
| Dec 31, 2021 | — | $-287.10M | -3.81 | $-37.43M |
Latest balance sheet: total assets $191.18M, total liabilities $130.34M, cash $82.92M (as of Jun 30, 2026).
CHRS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $1.45 |
| May 11, 2026 | 8-K Item 2.02 (results) | $1.95 |
| Mar 9, 2026 | 8-K Item 2.02 (results) | $1.93 |
| Jan 13, 2026 | 8-K Item 2.02 (results) | $1.70 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $1.49 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $0.88 |
| May 12, 2025 | 8-K Item 2.02 (results) | $1.02 |
| Mar 10, 2025 | 8-K Item 2.02 (results) | $1.04 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $1.47 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $0.72 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Biogen (BIIB)Halozyme Therapeutics (HALO)Vaxcyte (PCVX)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on CHRS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: intraday data as of Oct 19, 2026, 12:05 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.